This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Renal Diseases, Other  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2006;296:155-157.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—New phase 3 clinical trial results point to the potential of several targeted therapies for the treatment of patients with metastatic renal cell carcinoma, a disease with few therapeutic options and an annual worldwide mortality exceeding 100 000.

The studies, presented at the annual meeting of the American Society of Clinical Oncology, held here in June, may change the standard of care for patients with this disease. "The results are likely to lead to an expansion of treatment options for patients with metastatic renal cancer," said Michael Atkins, MD, of the Beth Israel Deaconess Medical Center's division of Hematology/Oncology, in Boston. "Today, targeted therapy enters the front line for the treatment of renal cancer," he added.

Targeted therapies in development or currently available for metastatic renal cell carcinoma, a disease that kills more than 100 000 people annually, should expand patients' treatment options.

SUNITINIB STUDY RESULTS

One drug of interest has . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions
Signoretti et al.
Clin. Cancer Res. 2008;14:3699-3705.
ABSTRACT | FULL TEXT